Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers
In 2016, the World Health Organization (WHO) updated its brain tumor classification system to recognize the importance of key genetic alterations in glioma, incorporating these features into the definitions of a variety of brain tumors for the first time. Several of these genetic alterations, such as IDH mutation and 1p/19q codeletion, can be assessed at imaging, with approaches including visual inspection, advanced MR and PET techniques, and machine learning reported in the literature. Reliable noninvasive assessment of these genetic features by imaging may allow for improved treatment planning and patient counseling, and an understanding of how the various genetically defined tumor types respond to therapy is useful in interpretation of post-treatment imaging. In the future, the importance of genetic features in glioma diagnosis and treatment will only increase, and it is incumbent upon neuroradiologists to stay abreast of these developments in order to provide optimal patient care.
KeywordsWorld Health Organization (WHO) IDH Mutation 1p/19q Codeletion Genetics Glioma Classification
- 1.Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization histological classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2007.Google Scholar
- 3.Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–18.CrossRefGoogle Scholar
- 9.Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neuro-Oncol. 2015;121(1):141–50.CrossRefGoogle Scholar
- 29.Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol. 2017;133(3):417–29.CrossRefGoogle Scholar